- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05046236
Interactive POWER Rehabilitation System on Rehabilitation Training for Patients With Parkinson's Disease
Developing Visual Feedback-aided Power Rehabilitation System and Exploring Its' Applications on Rehabilitation Training for Patients With Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease (PD) is a progressive neurodegenerative disease of the central nervous system with complex etiology. This disease is related to the consumption of dopamine in the substantia nigra of the brain, and it is currently believed that the main factors of consumption of dopamine are (1) heredity (2) aging (3) environment.
At present, there are many rehabilitation treatments available for patients with Parkinson's disease, such as: progressive resistance training, yoga, Tai Chi, dancing, cognitive training, balance training, gait training, bicycle, and treadmill training, etc. During the recent years, the POWER rehabilitation system from Japan (Procedure Outcome Worthwhile for Elderly Rehabilitation, referred to as POWER rehabilitation) including six types of equipment for strengthening different body parts has been applied to frail elderly or neurological patients gradually.
Parkinson's patients are often considered to have major difficulties in responding to motion disturbances (inability to respond appropriately), leading to learning, insufficient attention and motivation problems. Therefore, maintenance of motivation and feedback on performance are key factors that affect the participation of exercises in patients with Parkinson's disease.
The application of virtual reality in patients with PD is becoming more and more effective. An integrated rehabilitation system can not only enable the clinicians to check the rehabilitation status during the treatment, but also provide feedbacks to the patient through the interactive visual feedback screen. For Parkinson's patients, providing visual feedback through virtual reality intervention may be of particular clinical value.
In the first phase of this study, a virtual reality-like visual feedback system will be developed and combined with the original "POWER rehabilitation system" to form the so-called "Interactive POWER Rehabilitation System", and then system verification will be carried out. In the second phase of this study, this newly developed system will be applied to the rehabilitation training for patients with Parkinson's disease, and to explore whether the combination of POWER rehabilitation with visual feedback can produce the clinical benefits, as well as improving the daily life of patients with PD. Patients will be randomly assigned into three groups: interactive POWER, functional training, and control group. Single blind data collection will be used. Patients will be evaluated at baseline and post 12-week interventions. Outcome measures will include mini-BESTest, Unified Parkinson's disease rating scale, muscle strength of upper and lower extremities, timed up and go, 6-minute walking test, gait, and Parkinson's disease questionnaire PDQ-39.
It is expected that the "Interactive POWER Rehabilitation System" can promote the learning ability of patients with Parkinson's disease by adding visual feedbacks and enhance the treatment effects. It also offer rehabilitation clinicians more treatment options, lower the administrative costs of supporting staffs, reduce commuting costs for the patients, and elevate patients' desire to comply with the treatment program.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Szu-Min Fu, Student
- Phone Number: 886-982202892
- Email: szuminfu.be09@nycu.edu.tw
Study Contact Backup
- Name: Wei-Di Chen, Student
- Phone Number: 886-966070329
- Email: wdcdino0329.be09@nycu.edu.tw
Study Locations
-
-
-
New Taipei City, Taiwan, 220
- Recruiting
- Far Eastern Memorial Hospital
-
Contact:
- Chao-Chun Huang, Bachelor
- Phone Number: 866-2-77281501
-
New Taipei City, Taiwan
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Si-Huei Lee, PhD
- Phone Number: 886-938591985
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria of phase I study
- Healthy Volunteer (can walk 15 meters independently or with assistive devices).
- Aged 20-70 years old.
- Mini-mental state examination (MMSE) points above 24.
- Not familiar with POWER rehabilitation machines before this study.
- Able to understand POWER rehabilitation training and test items.
- Able to use smart devices and be willing to cooperate with pre-acceptance instructions.
- Able to communicate in Mandarin or Taiwanese, and be able to clearly express uncomfortable feelings.
- Willing to participate in this study after explanations, and sign the subject's informed consent.
Inclusion Criteria of phase II study
- Diagnosed as Idiopathic Parkinsonism by Neurologist
- PD stages of I-III according to the modified Hoehn and Yahr Scale
- Aged 45-85 years old
- Mini-mental state testing (MMSE) 24 points or more
- Stable medication regimen for at least 2 weeks before the trial
- Can walk 15 meters independently or with devices
- Able to understand treatment and assessment
- Able to understand and be willing to agree to the informed consent form
Exclusion Criteria of phase I study
- People who do not use smart devices and are unwilling to cooperate with the pre-acceptance instructions.
- Have severe hearing or vision impairments.
- Pregnant or breast-feeding.
- Any chronic condition that may cause safety concerns.
- Having any diseases which are contraindications for exercise participation.
- Muscle strength is affected by taking drugs.
- Have been to the gym 6 months before participating in the study (e.g. aerobic exercise, resistance training).
- Severe orthopedic diseases (unhealed fractures, severe joint destructions, and joints with fixed deformities, etc.).
- Severe or unstable neurological or cardiopulmonary diseases (severe cases of stroke and myocardial infarction in the acute phase, arrhythmia or uncontrolled blood pressure, etc.).
- Diagnosed with any mental illness (e.g., depression, psychosis or other mental illnesses)
- Unwilling to participate in this research.
Exclusion Criteria of phase II study
- Rheumatism
- Cardiovascular diseases or respiratory diseases (e.g., angina pectoris, pulmonary embolism, etc.)
- Severe or unstable neurological or orthopedic diseases.
- Severe hearing or vision impairments
- Diagnosed with any mental illness(e.g., depression, psychosis or other mental illnesses)
- A history of epilepsy.
- Pregnancy or pregnancy
- Any uncontrolled disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group
Usual care
|
|
|
Experimental: Interactive POWER rehabilitation
Participants in this group would be treated with POWER for twice a week, total 12 weeks.
|
Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
|
|
Active Comparator: Conventical physical training Group
Participants in this group would be treated with traditional exercise rehabilitation for twice a week, total 12 weeks.
|
Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Unified Parkinson's Disease Rating Scale at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
A comprehensive assessment of both motor and non-motor symptoms associated with Parkinson's.
The Unified Parkinson's Disease Rating Scale is made up of 42 items.
These items are divided into six sections which are separately "evaluation of mentation, behavior, and mood", "self-evaluation of the activities of daily life", "clinician-scored monitored motor evaluation", "complications of therapy", "Hoehn and Yahr staging of severity of Parkinson's disease" and "Schwab and England ADL scale".The evaluation score for the first item to the 39th item is 0 to 4 points.
The evaluation score for the 40th to the 42th item is 0 to 1 points.
The higher score meand the worse condition.
The sum of all the items'score is the score of the scale.
Higher Rating Scales'scores indicate severe symptoms.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline he Parkinson's Disease Questionnaire (PDQ-39) at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
The 39-point PDQ provides scores for each of the 8 scales: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communications and bodily discomfort.
It is used to assess the overall health-related quality of life profile of the individual questioned.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline the Mini-Mental State Exam (MMSE) at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
A widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills.
The score of 24 or more (out of 30) indicates a normal cognition.
Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.
The raw score may also need to be corrected for educational attainment and age.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline the Timed Up and Go test (TUG) at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
A simple test used to assess a person's mobility and requires both static and dynamic balance. It measures the time that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees. |
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline Mini-BESTest at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
The scale includes four items: (1) anticipatory balance, (2) reactive posture control, (3) sensory orientation, and (4) dynamic gait, A total of 14 measurement items, 2 points for each question, a total of 28 points.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline six minute walk test (6MWT) at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
Walk for six minutes at the subject's preferred speed and assistive devices.
You can stop at any time in the middle.
After the end, the walking distance will be recorded, and changes in heartbeat, blood pressure, blood oxygen saturation, dyspnea and fatigue will be monitored.
It will also end at the end then evaluate the walking distance.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline muscle strength of upper limbs at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
Use a hand-grip dynamometer to test the grip strength.
Both hands need to be measured twice individually, with a rest time of at least 30 seconds between the two.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline muscle strength of lower limbs at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
Use Micro FET3 instrument to measure knee joint extension and flexion; hip joint abduction and flexion muscle strength.
Each muscle group needs to be tested twice, with a 30-second rest between the two, and two recordings Take the maximum value afterwards.
|
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline gait Speed at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
The subjects were asked to wear an inertial sensor "Physilog®" (Gait Up, Lausanne, Switzerland) on each foot during a 10-meter walking test to collect gait data. Spatiotemporal gait parameters were calculated with the Gait Analysis Software provided by Gait Up, including the following lists. Stopwatch will also be employed by the operator to measure the walking time simultaneously. - Speed (m/s): Mean walking stride velocity of forward walking |
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline cadence at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
The subjects were asked to wear an inertial sensor "Physilog®" (Gait Up, Lausanne, Switzerland) on each foot during a 10-meter walking test to collect gait data. Spatiotemporal gait parameters were calculated with the Gait Analysis Software provided by Gait Up. - Cadence (step/minute): Number of steps in a minute |
Baseline and post-intervention at 12 weeks
|
|
Change from Baseline stride length at 12 weeks
Time Frame: Baseline and post-intervention at 12 weeks
|
The subjects were asked to wear an inertial sensor "Physilog®" (Gait Up, Lausanne, Switzerland) on each foot during a 10-meter walking test to collect gait data. Spatiotemporal gait parameters were calculated with the Gait Analysis Software provided by Gait Up. - Stride length (m): Distance between two consecutive footprints on the ground |
Baseline and post-intervention at 12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Si-Huei Lee, PhD, Taipei Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-05-004A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Bezmialem Vakif UniversityIstanbul University - CerrahpasaNot yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
Clinical Trials on Interactive POWER rehabilitation
-
Universidade da MadeiraCompletedStroke | Motor Activity | Self Efficacy | Social InteractionPortugal
-
The Catholic University of KoreaUnknownOsteoarthritis, Knee | Arthroplasty | Rehabilitation
-
Taipei Veterans General Hospital, TaiwanUnknown
-
Gulf Medical UniversityCompletedCoronary Artery Disease | Coronary Disease | Coronary Arteriosclerosis | Coronary Syndrome | Heart Diseases, IschemicUnited Arab Emirates
-
Riphah International UniversityCompletedCoronary Artery DiseasePakistan
-
Barretos Cancer HospitalUnknown
-
I.R.C.C.S. Fondazione Santa LuciaIole IndovinaNot yet recruitingDizziness | Rehabilitation | Vestibular Disorder | Balance
-
Kaohsiung Medical University Chung-Ho Memorial...CompletedDevelopmental DisabilityTaiwan
-
IRCCS San Raffaele RomaUniversità degli Studi di Ferrara; I.R.C.C.S. Fondazione Santa Lucia; Ministry... and other collaboratorsActive, not recruitingStroke | Upper Extremity ParesisItaly
-
University of ConnecticutUniversity of Central Florida; University of ToledoActive, not recruiting